NeuroMetrix Valuation
| NURO Stock | USD 4.25 0.03 0.71% |
At this time, the firm appears to be undervalued. NeuroMetrix secures a last-minute Real Value of $15.49 per share. The latest price of the firm is $4.25. Our model forecasts the value of NeuroMetrix from analyzing the firm fundamentals such as Current Valuation of (6.01 M), profit margin of (2.04) %, and Return On Equity of -0.43 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting NeuroMetrix's valuation include:
Price Book 0.5433 | Enterprise Value -6 M | Enterprise Value Ebitda 1.4581 | Price Sales 2.2879 | Enterprise Value Revenue 0.245 |
Undervalued
Today
Please note that NeuroMetrix's price fluctuation is not too volatile at this time. Calculation of the real value of NeuroMetrix is based on 3 months time horizon. Increasing NeuroMetrix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NeuroMetrix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeuroMetrix Stock. However, NeuroMetrix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.25 | Real 15.49 | Target 50.0 | Hype 4.17 |
The intrinsic value of NeuroMetrix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NeuroMetrix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NeuroMetrix helps investors to forecast how NeuroMetrix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeuroMetrix more accurately as focusing exclusively on NeuroMetrix's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use NeuroMetrix's intrinsic value based on its ongoing forecasts of NeuroMetrix's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against NeuroMetrix's closest peers.
NeuroMetrix Cash |
|
NeuroMetrix Valuation Trend
Knowing NeuroMetrix's actual value is paramount for traders when making sound investment determinations. Using both NeuroMetrix's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
NeuroMetrix Total Value Analysis
NeuroMetrix is now projected to have valuation of (6.01 M) with market capitalization of 8.62 M, debt of 240.88 K, and cash on hands of 20.83 M. The negative valuation of NeuroMetrix may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the NeuroMetrix fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(6.01 M) | 8.62 M | 240.88 K | 20.83 M |
NeuroMetrix Investor Information
About 25.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.54. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeuroMetrix recorded a loss per share of 4.51. The entity last dividend was issued on the 28th of March 2007. The firm had 1:8 split on the 22nd of November 2023. Based on the key measurements obtained from NeuroMetrix's financial statements, NeuroMetrix is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.NeuroMetrix Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NeuroMetrix has an asset utilization ratio of 27.55 percent. This suggests that the Company is making $0.28 for each dollar of assets. An increasing asset utilization means that NeuroMetrix is more efficient with each dollar of assets it utilizes for everyday operations.NeuroMetrix Ownership Allocation
NeuroMetrix holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.NeuroMetrix Profitability Analysis
The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (6.53 M) with profit before overhead, payroll, taxes, and interest of 5.75 M.About NeuroMetrix Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of NeuroMetrix. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NeuroMetrix based exclusively on its fundamental and basic technical indicators. By analyzing NeuroMetrix's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of NeuroMetrix's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of NeuroMetrix. We calculate exposure to NeuroMetrix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NeuroMetrix's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.9 M | 3.8 M | |
| Pretax Profit Margin | (1.11) | (1.16) | |
| Operating Profit Margin | (1.21) | (1.27) | |
| Net Loss | (1.11) | (1.16) | |
| Gross Profit Margin | 0.67 | 0.66 |
NeuroMetrix Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1 M |
NeuroMetrix Current Valuation Indicators
NeuroMetrix's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final NeuroMetrix's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as NeuroMetrix, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use NeuroMetrix's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes NeuroMetrix's worth.When determining whether NeuroMetrix offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeuroMetrix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurometrix Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurometrix Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.51) | Revenue Per Share 2.157 | Quarterly Revenue Growth (0.51) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.